Healthcare Industry News: Integrated BioPharma
News Release - January 3, 2006
ImClone Systems Names Cheryl Anderson Vice President, Regulatory AffairsNEW YORK--(HSMN NewsFeed)--Jan. 3, 2006--ImClone Systems Incorporated (NASDAQ: IMCL ) announced today that it has named Cheryl Anderson Vice President, Regulatory Affairs. In this role, Ms. Anderson will be responsible for developing and executing ImClone Systems' strategy for addressing all regulatory issues on a global basis. Ms. Anderson will supervise the Regulatory Affairs functions of the Company related to clinical therapeutic development, compliance, safety, and manufacturing, and will report directly to Eric K. Rowinsky, M.D., Senior Vice President and Chief Medical Officer of ImClone Systems.
Ms. Anderson has held senior regulatory positions at a number of pharmaceutical companies, including Bayer, where she served as Vice President of North America and Global Oncology, Regulatory Affairs; Aventis, where she served as Senior Director and Therapeutic Area Head of Global Oncology Regulatory Liaison; and Bristol-Myers Squibb, where she served most recently as Group Director of Global Oncology Regulatory Sciences. Ms. Anderson received her B.S. degree in biochemistry from Southern Connecticut State University.
The Company has made an inducement stock option grant to Ms. Anderson for the right to purchase 51,000 shares of the Company's common stock. These stock options will vest over a four year period, and have an exercise price equal to the closing price of ImClone Systems' common stock on January 3, 2005. The stock options were granted under the ImClone Systems 2005 Inducement Stock Option Plan, as approved by the Compensation Committee of ImClone Systems' Board of Directors. This stock option grant meets the "employee inducement" exception to NASDAQ Marketplace Rule 4350 requiring shareholder approval of equity-based incentive plans.
About ImClone Systems Incorporated
ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully Integrated BioPharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.
Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Source: ImClone Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.